Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2008-04-29
2008-04-29
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S184100
Reexamination Certificate
active
10820816
ABSTRACT:
The present invention relates to peptides, referred to as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2 and C-20 peptides, which are antigenic and elicit a protective immune response against HIV infection. Compositions, pharmaceutical compositions and vaccines comprising these antigenic peptides are also encompassed by the present invention, as well as neutralizing antibodies which inhibit infection of primary CD4+ T lymphocytes by various HIV isolates. Methods for diagnosis of HIV are also disclosed.
REFERENCES:
patent: 4629783 (1986-12-01), Cosand
patent: 6042836 (2000-03-01), Berman et al.
patent: 6447778 (2002-09-01), Rubinstein et al.
patent: 6455265 (2002-09-01), Serres
patent: 0 219 106 (1987-04-01), None
patent: 0 219 106 (1987-04-01), None
patent: 0 387 914 (1990-09-01), None
patent: WO 02/053587 (2002-07-01), None
patent: WO 02/053587 (2002-07-01), None
Dong et al. N-and C domains of HIV-1 gp41: mutation, structure and functions. Immunology Letters, 2001, vol. 75, p. 215-220.
Greenberg. Possible protective efffect of HIV-2 against incident HIV-1 infection: review of avilable epidemioligical and in vitro data. AIDS, 2001, vol. 15, p. 2319-2321.
Feinberg et al.AIDS vaccine models: Challenging challenge viruses. Nature Medicine, 2002, vol. 8, p. 207-210.
McMichael et al. HIV vaccines 1983-2003. Nature Medicine, 2003, vol. 9, p. 874-880.
Xu et al. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Virology, vol. 349, p. 276-289.
Pazner. Identifying epitopes of HIV-1 that induce protective antibodies. Nature Immunology, 2004, vol. 4, p. 199-210.
Baker et al. Protein structure prediction and structural genomics. Science, 2001, vol. 294, p. 1-7.
Attwood et al. The babel of bioinformatics. Science, 2000, vol. 290, p. 1-6.
diMarzo et al. Loss of a neutralizing epitope by a spontaneous point mutation in the V3 loop of HIV-1 isolated from an infected laboratory worker. The journal of biological chemistry, 1993, vol. 268, p. 25894-25901.
Abaza et al. Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 15-22. Journal of protein chemistry, 1992, vol. 11, p. 445454.
Goldstein et al. Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains. Vaccine, 2001, vol. 19, p. 1738-1746.
Tam. Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system. PNAS, 1988, vol. 85, p. 5409-5413.
Malashkevich, V. N. et al., “Crystal Structure of the Simian Immunodeficiency Virus (SIV) gp41 Core: Conserved Helical Interactions Underlie the Broad Inhibitory Activity of gp41 Peptides”, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 9134-9139, (Aug. 1998).
Couet, J. et al., “Identification of Peptide and Protein Ligands for the Caveolin-Scaffolding Domain”, The Journal of Biological Chemistry, vol. 272, No. 10, Issue of Mar. 7, pp. 6525-6533, (1997).
Llano, M. et al., “Blockage of Human Immunodeficiency Virus Type 1 Expression by Caveolin-1”, Journal of Virology, vol. 76, No. 18, pp. 9152-9164, (Sep. 2002).
Campbell, S. M. et al., “Lipid Rafts and HIV-1: from Viral Entry to Assembly of Progeny Virions”, Journal of Clinical Virology 22, pp. 217-227, (2001).
Kilby et al., Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry,Nature Medicine, vol. 1:11 (1998) pp. 1-7.
Briand Jean-Paul
Hovanessian Ara
Krust Bernard
Muller Sylviane
Said Elias
Boesen Agnieszka
Campell Bruce R.
Centre National de la Recherche Scientifique
Finnegan Henderson Farabow Garrett & Dunner LLP
Institut Pasteur
LandOfFree
Synthetic peptide vaccines for HIV: the CBD epitope as an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic peptide vaccines for HIV: the CBD epitope as an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic peptide vaccines for HIV: the CBD epitope as an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3946168